Teva gets FDA OK for Quartette 91-day oral contraceptive
This article was originally published in Scrip
Executive Summary
The US FDA has granted its OK for Teva to market its extended regimen oral contraceptive Quartette (levonorgestrel/ethinyl estradiol and ethinyl estradiol) to prevent pregnancy.